BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Syngene International Ltd. reported mixed set of numbers in Q2, where the top-line growth has been healthy at 12% YoY (dollar term revenue growth - 10%) led by discovery services and steady traction in dedicated research and development segment.
However, Ebitda margins were weak at 28.7% (down 60 basis points YoY, 170 basis points QoQ).
Operational expenses from Mangalore active pharmaceutical ingredient plant along with front loaded costs of employee ESOP plan (to be amortized over a period of time) impacted margins.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR